In the context of the coronavirus disease 2019 (COVID-19) pandemic, we aimed to evaluate the impact of anti-cytokine therapies (AT) in kidney transplant recipients requiring hospitalization due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. This is an observational retrospective study, which included patients from March to May 2020. An inverse probability of treatment weighting from a propensity score to receive AT was used in all statistical analyses, and we applied a bootstrap procedure in order to calculate an estimation of the 2.5th and 97.5th percentiles of odds ratio (OR). outcomes were measured using an ordinal scale determination (OSD). A total of 33 kidney recipients required hospitalization and 54% of them received at least one AT, mainly tocilizumab (42%), followed by anakinra (12%). There was no statistical effect in terms of intensive care unit (ICU) admission, respiratory secondary infections (35% vs. 7%) or mortality (16% vs. 13%) comparing patients that received AT with those who did not. Nevertheless, patients who received AT presented better outcomes during hospitalization in terms of OSD ≥5 ((OR 0.31; 2.5th, 97.5th percentiles (0.10; 0.72)). These analyses indicate, as a plausible hypothesis, that the use of AT in kidney transplant recipients presenting with COVID-19 could be beneficial, even though multicenter randomized control trials using these therapies in transplanted patients are needed.
【저자키워드】 COVID-19, Mortality, Infection, Kidney transplantation, anti-cytokine therapy, 【초록키워드】 Treatment, coronavirus disease, SARS-CoV-2, coronavirus, pandemic, therapy, intensive care, Hospitalization, Tocilizumab, outcome, ICU, kidney, Probability, Retrospective study, Secondary infection, Patient, multicenter, Admission, kidney transplant recipient, Hypothesis, randomized control trial, Analysis, Odds ratio, acute respiratory syndrome, statistical analyses, recipient, bootstrap, Weighting, statistical, was used, evaluate, required, applied, presenting, were measured, receive, calculate, with COVID-19, 【제목키워드】 Transplant, recipient, with COVID-19,